New drug combinations for advanced hormone-receptor positive breast cancer
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Skin clinical trials.
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be hormone-receptor positive and HER2 negative (a specific type confirmed by biopsy)
- Your cancer must be advanced or have spread and cannot be cured by surgery or radiation alone
- You must have received at least one prior cancer treatment
- You must have at least one tumor that can be measured on scans
- You must be in good enough health to tolerate the study drugs (ECOG score of 0 or 1)
- You cannot be pregnant or breastfeeding, and must use birth control if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (an Aurora A kinase inhibitor) combined with hormone therapy and HER2-targeted therapy for people with advanced HR+/HER2+ breast cancer whose disease has not gotten worse after initial treatment. The goal is to see if this combination can help prevent the cancer from becoming resistant to treatment.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.